Use of remdesivir for patients with Covid-19: a review article

Abstract

SUMMARY The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, SCIELO, LILACS, and PUBMED. On May 1, Remdesivir received emergency use authorization from the Food and Drug Administration. Remdesivir is currently the most promising molecule in the treatment of COVID-19, taking into account its broad antiviral spectrum (considering the genetic sequences of the virus, it is expected to maintain activity against SARS-CoV-2). There is in vitro and in vivo information available for coronaviruses, as well as an extensive clinical safety database (from a clinical trial of the Ebola virus and in the context of the Monitored Emergency Use of Unregistered and Investigational Interventions - MEURI). Further studies are relevant as available data on the efficacy and safety of Remdesivir against SARS-nCoV-2 are limited.

Glycophosphopeptical AM3 Food Supplement: A Potential Adjuvant in the Treatment and Vaccination of SARS-CoV-2

“…Still, Remdesivir is currently the most promising as it has been granted an Emergency Use Authorization by the United States Food and Drug Administration (FDA or USFDA) as it undergoes clinical trials Phase III. Remdesivir reduces the stay in intensive care, although without significant clinical effects (11). Another option is the use of several antivirals in combination (Lopinavir, Ritonavir, Ribavirin) associated with Interferon 1b which has been shown to reduce symptoms and reduce the temporality of the infective phases of COVID-19.…”

Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective

“…Structurally, they are nucleotide analogs that hinder the functions of endogenous nucleotides as building blocks during viral RNA synthesis. Due to their potent antiviral activity toward SARS-CoV-2, they were repurposed as a SARS-CoV-2 treatment (Cao et al 2020;Singh et al 2020;Pardo et al 2020;Azevedo et al 2020;Hashemian et al 2020;Frediansyah et al 2020).…”

Pandemia do SARS-COV-2: uma revisão integrativa sobre os principais medicamentos, aprovados ou em fase de estudos, que podem ser utilizados no tratamento da COVID-19

“…O antiviral remdesivir, desde maio de 2020 recebeu a aprovação da Food and Drug Administration (FDA) para uso emergencial em pacientes graves com COVID-19, sendo expandido seu uso, no final de agosto de 2020 para o tratamento de pacientes com quadro moderado da doença (Ferreira & Andricopulo, 2020). Estudos demonstraram que as doses intravenosas de Remdesivir foram adequadamente toleradas nos pacientes; este medicamento não foi utilizado em pacientes gravemente infectados pelo COVID-19, necessitando de ensaios clínicos de controle (Azevedo et al, 2020).…”